Norwegian pharmaceutical company Ultimovacs ASA (Oslo:ULTI) announced on Monday a Phase II DOVACC collaboration study in ovarian cancer with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN).
The randomised Phase II clinical trial will evaluate Ultimovacs' proprietary universal cancer vaccine, UV1, in combination with AstraZeneca's durvalumab, a PD-L1 checkpoint inhibitor, and its PARP inhibitor, olaparib, in patients with relapsed ovarian cancer.
More than 30 hospitals in around 10 European countries will participate in the trial. Topline data on the primary endpoint is expected in 2023.
Ultimovacs will provide its UV1 vaccine and AstraZeneca will provide the PD-L1 and PARP inhibitors for the study. Innovation Norway has granted Ultimovacs NOK10m (approximately EUR1m) to support the execution of the trial.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886